A Win For Apimeds Pharmaceuticals US, Inc
Tue, Oct 06, 2026 at 08:15 PM
Apimeds Pharmaceuticals US, Inc (APUS:NYSEMKT) soared at $7.13, a gain of 55.3%. On Tue, Oct 06, 2026, APUS:NYSEMKT touched a New 2-Week Intraday High of $8.39. The stock appeared on our News Catalysts scanner on Mon, Oct 05, 2026 at 09:11 AM in the 'AGREEMENT' category. From Tue, Sep 22, 2026, the stock recorded 50.00% Up Days and 36.36% Green Days
The stock spiked on Fri, Sep 25, 2026 at $9.14 with a volume of 37M+.
About Apimeds Pharmaceuticals US, Inc (APUS:NYSEMKT)
Apimeds Pharmaceuticals US is a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits...
Top 10 Gainers:
- The OLB Group, Inc. (OLB:NASDAQ), 117.85%
- Mobix Labs, Inc. (MOBX:NASDAQ), 72.28%
- Apimeds Pharmaceuticals US, Inc (APUS:NYSEMKT), 55.34%
- VCI Global Limited (VCIG:NASDAQ), 54.78%
- TEN Holdings, Inc. (XHLD:NASDAQ), 51.58%
- Professional Diversity Network, Inc. (IPDN:NASDAQ), 48.71%
- SolarMax Technology, Inc. (SMXT:NASDAQ), 44.3%
- Olenox Industries Inc Com Par $0.01 Aug 2025 (OLOX:NASDAQ), 42.05%
- Option Care Health, Inc. (OPCH:NASDAQ), 32.65%
- Freight Technologies, Inc. (FRGT:NASDAQ), 31.43%